CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $24,116 | $21,083 | $18,241 | $12,329 |
| % Growth | 14.4% | 15.6% | 48% | – |
| Cost of Goods Sold | $1,224 | $1,167 | $1,152 | $917 |
| Gross Profit | $22,892 | $19,916 | $17,089 | $11,412 |
| % Margin | 94.9% | 94.5% | 93.7% | 92.6% |
| R&D Expenses | $10,211 | $11,922 | $8,220 | $8,705 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $21,913 | $23,692 | $21,498 | $21,590 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2,102 | -$411 | $0 |
| Operating Expenses | $32,124 | $33,512 | $29,307 | $30,295 |
| Operating Income | -$9,232 | -$13,596 | -$12,218 | -$18,883 |
| % Margin | -38.3% | -64.5% | -67% | -153.2% |
| Other Income/Exp. Net | -$4,190 | -$3,862 | -$3,487 | -$3,771 |
| Pre-Tax Income | -$13,422 | -$17,458 | -$15,705 | -$22,654 |
| Tax Expense | $8,373 | -$532 | -$77 | $10 |
| Net Income | -$21,795 | -$16,926 | -$15,628 | -$22,664 |
| % Margin | -90.4% | -80.3% | -85.7% | -183.8% |
| EPS | -0.17 | -0.13 | -0.13 | -0.21 |
| % Growth | -30.8% | 0% | 38.1% | – |
| EPS Diluted | -0.17 | -0.13 | -0.13 | -0.21 |
| Weighted Avg Shares Out | 131,566 | 128,426 | 121,597 | 108,529 |
| Weighted Avg Shares Out Dil | 131,566 | 128,426 | 121,597 | 108,529 |
| Supplemental Information | – | – | – | – |
| Interest Income | $866 | $1,022 | $435 | $212 |
| Interest Expense | $5,049 | $3,751 | $3,999 | $3,973 |
| Depreciation & Amortization | $1,386 | -$111 | $967 | $782 |
| EBITDA | -$7,846 | -$13,707 | -$11,251 | -$18,101 |
| % Margin | -32.5% | -65% | -61.7% | -146.8% |